CTLA4 and melanoma: Overall, nivolumab (anti-PD-1), pembrolizumab (anti-PD-1), and ipilimumab (anti-CTLA-4) have shown sustained tumor regression, decreased recurrence rates, and prolonged overall survival in melanoma [106,107].